These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35510600)

  • 21. Identification of Phytochemicals from Arabian Peninsula Medicinal Plants as Strong Binders to SARS-CoV-2 Proteases (3CL
    Saquib Q; Bakheit AH; Ahmed S; Ansari SM; Al-Salem AM; Al-Khedhairy AA
    Molecules; 2024 Feb; 29(5):. PubMed ID: 38474509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular modelling on SARS-CoV-2 papain-like protease: an integrated study with homology modelling, molecular docking, and molecular dynamics simulations.
    Arwansyah A; Arif AR; Ramli I; Kurniawan I; Sukarti S; Nur Alam M; Illing I; Farid Lewa A; Manguntungi B
    SAR QSAR Environ Res; 2021 Sep; 32(9):699-718. PubMed ID: 34392751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease.
    Choudhary S; Nehul S; Singh A; Panda PK; Kumar P; Sharma GK; Tomar S
    IUBMB Life; 2024 May; 76(5):228-241. PubMed ID: 38059400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2.
    Islam R; Parves MR; Paul AS; Uddin N; Rahman MS; Mamun AA; Hossain MN; Ali MA; Halim MA
    J Biomol Struct Dyn; 2021 Jun; 39(9):3213-3224. PubMed ID: 32340562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disrupting protease and deubiquitinase activities of SARS-CoV-2 papain-like protease by natural and synthetic products discovered through multiple computational and biochemical approaches.
    Waqas M; Ullah S; Ullah A; Halim SA; Rehman NU; Khalid A; Ali A; Khan A; Gibbons S; Csuk R; Al-Harrasi A
    Int J Biol Macromol; 2024 Oct; 277(Pt 4):134476. PubMed ID: 39111477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2.
    Patel D; Athar M; Jha PC
    J Biomol Struct Dyn; 2022 Apr; 40(7):3071-3081. PubMed ID: 33200683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2.
    Muhseen ZT; Hameed AR; Al-Hasani HMH; Ahmad S; Li G
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33525411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation.
    Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K
    J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
    Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
    Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential targets of severe acute respiratory syndrome coronavirus 2 of clinical drug fluvoxamine: Docking and molecular dynamics studies to elucidate viral action.
    Panda SK; Gupta PSS; Rana MK
    Cell Biochem Funct; 2023 Jan; 41(1):98-111. PubMed ID: 36478589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study.
    Singh AK; Kushwaha PP; Prajapati KS; Shuaib M; Gupta S; Kumar S
    Comput Biol Med; 2021 Mar; 130():104185. PubMed ID: 33352458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation.
    Rao P; Patel R; Shukla A; Parmar P; Rawal RM; Saraf M; Goswami D
    Mol Divers; 2022 Feb; 26(1):309-329. PubMed ID: 33825097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An ISG15-Based High-Throughput Screening Assay for Identification and Characterization of SARS-CoV-2 Inhibitors Targeting Papain-like Protease.
    Samrat SK; Kumar P; Liu Y; Chen K; Lee H; Li Z; Chen Y; Li H
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.
    Osipiuk J; Azizi SA; Dvorkin S; Endres M; Jedrzejczak R; Jones KA; Kang S; Kathayat RS; Kim Y; Lisnyak VG; Maki SL; Nicolaescu V; Taylor CA; Tesar C; Zhang YA; Zhou Z; Randall G; Michalska K; Snyder SA; Dickinson BC; Joachimiak A
    Nat Commun; 2021 Feb; 12(1):743. PubMed ID: 33531496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacophore model-aided virtual screening combined with comparative molecular docking and molecular dynamics for identification of marine natural products as SARS-CoV-2 papain-like protease inhibitors.
    Thangavel N; Albratty M
    Arab J Chem; 2022 Dec; 15(12):104334. PubMed ID: 36246784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Alesawy MS; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34771004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and characterization of aurintricarboxylic acid as a potential inhibitor of SARS-CoV-2 PLpro.
    Arya R; Prashar V; Kumar M
    Int J Biol Macromol; 2023 Mar; 230():123347. PubMed ID: 36682650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach.
    Sencanski M; Perovic V; Milicevic J; Todorovic T; Prodanovic R; Veljkovic V; Paessler S; Glisic S
    ChemistryOpen; 2022 Feb; 11(2):e202100248. PubMed ID: 35103413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19.
    Swargiary A; Mahmud S; Saleh MA
    J Biomol Struct Dyn; 2022 Mar; 40(5):2067-2081. PubMed ID: 33089730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.